Safety, tolerability, CYP2D6 and G6PD variant data from this study support the deployment of the WHO-recommended SLD primaquine without G6PD testing in South African districts with low-intensity residual transmission aiming to eliminate malaria. Here, CYP2D6 is linked to malaria.